O-1A Guide
O-1A for Bioprospecting and Natural Products Researchers: NIH and NSF Grant Records, Journal of Natural Products Publications, and O-1A Evidence
Natural products researchers discover compounds that become FDA-approved drugs — yet their O-1A evidence spans chemistry, microbiology, and pharmacology in ways USCIS rarely sees. This guide covers NIH NIGMS and NSF CHE grants, JNP and JACS publications, compound discovery evidence, and how to build a three-criterion case.
Natural products research and the O-1A evidence landscape
Natural products chemistry is the study of bioactive chemical compounds derived from biological organisms — bacteria, fungi, plants, marine invertebrates, and other sources. Researchers in this field engage in isolation and structure elucidation of novel compounds, biosynthetic pathway analysis, synthesis and semi-synthesis of complex natural products, and preclinical evaluation of compounds with pharmaceutical, agricultural, or materials science applications. The American Chemical Society (ACS) and the American Society of Pharmacognosy (ASP) are the primary professional bodies. The Journal of Natural Products, co-published by ACS and ASP, is the field's central archival journal. For O-1A petition purposes, natural products researchers working at the intersection of chemistry, microbiology, pharmacology, or marine biology must frame their petition around a clearly defined subdiscipline so the relevant peer comparison pool is appropriately scoped.
Under 8 C.F.R. § 214.2(o)(3)(iii), the O-1A extraordinary ability standard requires that the petitioner be among the small percentage at the top of their field. In natural products research, the top-of-field signals available for petition purposes include: funded research grants from NIH's National Institute of General Medical Sciences (NIGMS) under the Chemistry of Life Processes program or the National Cancer Institute (NCI) under its Natural Products Branch; NSF CHE (Chemistry Division) grants for natural product total synthesis; publications in Journal of Natural Products, Journal of Medicinal Chemistry, Journal of the American Chemical Society, and Organic Letters; and recognition from ASP including the Matt Suffness Award and the ASP Young Investigator Award.
The petition brief for a bioprospecting or natural products researcher should describe the field's societal and commercial context clearly. Natural products are the original source of approximately half of all FDA-approved small-molecule drugs, including antifungals such as amphotericin B, antibiotics in the macrolide and aminoglycoside classes, immunosuppressants such as rapamycin, and cancer therapeutics derived from the Vinca alkaloid and taxane families. This commercial and medical significance frames why extraordinary achievement in the field matters, and why the petitioner's specific contributions — whether to discovery, synthesis, or biosynthetic engineering — carry real-world weight beyond academic recognition.
NIH and NSF grant records as awards-criterion evidence
NIH NIGMS grants under the Chemistry of Life Processes program are awarded following peer review by Scientific Review Groups (SRGs) and council review, with proposals receiving priority score and percentile rankings. A funded R01, R35, or U19 grant from NIGMS is strong evidence for the awards criterion when the petition brief explains the competitive scoring process: NIGMS funds fewer than 20% of competing applications in most cycles, and a grant with a low percentile score reflects that study section members — expert peers in the field — assessed the application as outstanding. The petition should include the NIH award notice and the funded abstract.
NSF Chemistry Division (CHE) grants for natural product synthesis or medicinal chemistry are awarded through a similar competitive peer review process. NSF CAREER Awards for assistant professors in natural products chemistry are particularly strong evidence because they carry an explicit merit-review finding that the petitioner is an outstanding early-career researcher in the field. The NCI's Natural Products Branch also contracts specific natural products discovery and synthesis work, and a researcher awarded an NCI contract or supplement under this branch has received recognition from a federal agency expert in the therapeutic potential of natural products research.
Extramural grants from pharmaceutical industry partners — for example, sponsored research agreements with established pharmaceutical firms specifically for natural products lead compound development — can supplement federal grant evidence under the original contributions criterion. The petition brief should explain that pharmaceutical companies fund academic natural products research only when the researcher's compound discovery or synthesis expertise represents a capability the company cannot replicate internally, which reflects recognition of distinction from an outside organization. These industry contracts do not substitute for peer-reviewed federal grants as awards evidence, but they strengthen the original contributions and critical role narratives.
Publication records in Journal of Natural Products and high-impact chemistry journals
The Journal of Natural Products (JNP), co-published by ACS and ASP, is the primary archival venue for isolation, structure elucidation, and biological activity papers in natural products chemistry. Under 8 C.F.R. § 214.2(o)(3)(iii)(E), publications in a professional journal in the field satisfy the scholarly articles criterion. The petition should document JNP papers with their DOIs, journal impact factor for the years published, and citation counts from Web of Science or Scopus. For researchers who also publish in higher-impact chemistry journals — JACS, Angewandte Chemie, Nature Chemistry, or Nature Products and Chemical Biology — those papers are typically the most-cited and should be foregrounded in the scholarly articles exhibit.
Citation analysis is particularly useful for natural products researchers whose landmark papers document the first isolation and structure of a novel compound class. A paper reporting the discovery of a new antibiotic scaffold or an anticancer compound that enters clinical development will accumulate citations from medicinal chemists, microbiologists, structural biologists, and clinical researchers across disciplines — a citation footprint that extends well beyond the natural products community itself. The petition should include a citation list organized by subdiscipline to illustrate how broadly the petitioner's discovery has influenced adjacent fields.
Review articles in Natural Product Reports (RSC) and Chemical Reviews (ACS) covering natural products topics are strong supplementary evidence when the petitioner is invited to contribute. Both journals publish by invitation or solicitation, and an invited contribution reflects peer recognition of the petitioner's expertise. The petition should document the editorial invitation, note that Natural Product Reports does not accept unsolicited review submissions, and include citation counts for the review article to show how widely it has been read and referenced.
Original contributions and compound discovery evidence
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(iii)(E) asks for evidence of original scientific contributions of major significance. For natural products researchers, the most direct form is the discovery or first isolation of a novel compound with documented biological activity, particularly if the compound enters preclinical or clinical development. The petition should document the compound, the publication reporting its first isolation, the biological activity data, and any downstream development steps — including IND filings with FDA, NCI drug development contracts, or licensing agreements with pharmaceutical firms — that demonstrate the contribution's downstream significance.
Advances in biosynthetic gene cluster (BGC) analysis represent a category of original contributions increasingly recognized by USCIS in natural products petitions. A researcher who has developed or significantly advanced methods for BGC identification, genome mining for cryptic natural product pathways, or heterologous expression of silent biosynthetic clusters has contributed to a methodological shift that expanded accessible chemical diversity for the whole field. Publications describing these methods in Nature Chemical Biology, Metabolic Engineering, or mSystems, combined with citation records showing adoption of the method by other labs, document both the novelty and the field-wide impact of the contribution.
For petitioners working in marine natural products bioprospecting — sampling from deep-sea corals, sponges, tunicates, and microbial symbionts from poorly explored marine environments — the discovery record may include organisms that had never been chemically characterized. Expert letters from marine pharmacology researchers can contextualize why a discovery from an unexplored marine environment carries greater significance than characterizing a well-studied terrestrial organism, helping the petition brief connect the technical record to the extraordinary ability standard.
Critical role documentation and high salary benchmarks
The critical role criterion requires showing that the petitioner has played or will play a critical role for an organization of distinguished reputation. For natural products researchers, the most common qualifying roles are: principal investigator of an NIH or NSF grant-funded laboratory at a research university; principal investigator on an NCI Natural Products Branch contract; or a named project leader role at a federal laboratory with a natural products program, such as the USDA ARS Natural Products Utilization Research Unit in Oxford, Mississippi. The petition letter from the employing institution should confirm the petitioner's role as the designated scientific lead who cannot be replaced without disrupting the funded research program.
For industry-based natural products researchers — particularly those working at natural product-focused biotech companies or pharmaceutical firms with natural products discovery units — the critical role letter should come from a senior scientific officer who can explain that the petitioner's specific expertise in a compound class, organism type, or analytical technique is essential to the company's research pipeline. A researcher who is the sole expert in a proprietary dereplication workflow or a unique sample collection relationship represents a non-substitutable critical function, and the petition brief should articulate that specificity.
Salary benchmarks for natural products researchers depend on institutional sector. For academic chemists, AAUP salary survey data by field and rank provides the appropriate benchmark. For industry researchers, the BLS OEWS data for SOC 19-1021 (Biochemists and Biophysicists) or 19-2031 (Chemists) provides sector-specific percentile wage data. A natural products researcher employed at a pharmaceutical company or biotech firm who earns above the 90th percentile for the applicable SOC code and metropolitan area satisfies the high salary criterion and should include W-2 or offer letter documentation with the petition.
Assembling a complete O-1A file for natural products research
A well-structured O-1A petition for a bioprospecting or natural products researcher will build on a compound discovery or methodological advance that can be documented across multiple criteria simultaneously. A researcher who discovered a novel antimicrobial compound, published it first in JACS or JNP, attracted a subsequent NIH NIGMS R01 to pursue its biosynthesis, was invited to serve on the NIGMS SRG reviewing related proposals, and leads a graduate research laboratory at an R1 university will have evidence touching awards (NIH grant), scholarly articles (publications), judging (SRG service), original contributions (compound discovery), and critical role (PI of funded laboratory). That cross-criterion reinforcement is the goal.
Expert letters for natural products researchers should come from peers at other institutions who can evaluate the petitioner's work from the outside. The most persuasive letters come from researchers who are themselves recognized in the field — active grant holders, journal editors, ASP officers, or researchers at NCI's Natural Products Branch — and who can specifically describe why the cited publications or discoveries are significant. Letters that recite the petitioner's CV without explaining why the cited publications matter to the field add little value; letters that explain the significance of a specific discovery in technical terms USCIS can reference in an approval add substantial value.
Petitioners with early-career records who have not yet accumulated a long publication list should concentrate on depth rather than breadth in the petition. A researcher who can document two or three high-impact publications in JNP or JACS with strong citation records, a funded NIH R01, and NSF panel service has assembled a petition around signals that USCIS regularly credits — even if the total publication count is modest. The regulatory standard for O-1A is extraordinary ability at the time of filing, not career achievement measured over decades, and a strong early-career record that meets the evidentiary standard can support approval.
What we typically gather for this kind of case
| Document | Where to source | Why it matters |
|---|---|---|
| Peer-reviewed publications | Web of Science / Scopus exports | Anchors original-contributions and authorship criteria |
| Citation analysis | Google Scholar profile + ESI top-1% data | Quantifies major significance in the field |
| Salary benchmark | BLS OEWS for SOC code + locality | Documents high-salary criterion at 90th-percentile or above |
| Critical-role letters | Direct supervisor + program director | Establishes role's importance, not just title |
What we see go wrong, again and again
- 01Treating extraordinary ability as a credentials checklist rather than a story of field-wide impact.
- 02Submitting bibliometric data (h-index, citation counts) without explaining what makes those numbers high relative to peers in the same sub-field.
- 03Relying on letters from collaborators or co-authors rather than independent experts who can speak to influence.
See if you qualify
Lando reviews your background against the O-1A visa criteria and tells you honestly where you stand. Free, no commitment.